Price (delayed)
$6.97
Market cap
$15.1M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$14.33
Enterprise value
$28.71M
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop
There are no recent dividends present for ELOX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.